Guardant Health (GH) added nearly 10% at the market open on Friday to hit a new 52-week high after the blood-based cancer test maker reported Q2 2026 revenue well surpassing the consensus and raised its full-year outlook.
After the market Guardant Health (GH) added nearly 10% at the market open on Friday to hit a new 52-week high after the blood-based cancer test maker reported Q2 2026 revenue well surpassing the consensus and raised its full-year outlook
After the market